相关实验视频

Updated: Jul 2, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

对于高级非小细胞肺癌的赛米普利马布加化疗方案的经济评估

Yitian Lang¹, Yan Lin¹, Meng Deng¹

¹Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China.

|February 21, 2024

概括

以目前的价格来看,塞米普利马布加化疗对晚期非小细胞肺癌 (NSCLC) 不是具有成本效益的治疗方法. 增量成本效益比超过了美国纳税人典型的每QALY15万美元的门.

科学领域:

在瘤学瘤学.
卫生经济学卫生经济学
药物经济学药物经济学

背景情况:

塞米普利马布是一种PD-1抑制剂,在治疗晚期非小细胞肺癌 (NSCLC) 中表现有前途.
塞米普利马布与晚期NSCLC的化疗相结合的成本效益尚未得到充分确立.
这项研究从美国纳税人的角度评估了cemiplimab加化学疗法与仅用于高级NSCLC的化学疗法的经济价值.

研究的目的:

评估塞米普利马布加化学疗法的成本效益与晚期NSCLC的化学疗法相比.
为了确定这个治疗方案的增量成本效益比 (ICUR).
评估塞米普利马布在美国高级NSCLC治疗中的经济可行性.

主要方法:

用一个分区生存模型来模拟NSCLC的进展.
来自EMPOWER肺部3试验的数据被用于估计长期整体存活率 (OS) 和无进展存活率 (PFS).
进行了单向和概率灵敏度分析 (OWSA和PSA),以评估结果的可靠性.

主要成果:

基准案例CEMIPLIMAB加化疗的ICUR为每次质量调整寿命年 (QALY) 395,593.8美元.
在标准的支付意愿值下,PSA表明,塞米普利马布加化疗的成本效益概率为0%.
敏感性分析显示,结果对危险比率,效用值和塞米普利马布成本都很敏感.

结论:

在目前的价格下,Cemiplimab加化学疗法不太可能是高级NSCLC的成本有效选择.
估计的ICUR显著超过美国纳税人普遍接受的每QALY15万美元的门.
如果药物定价或临床数据发生变化,可能需要进一步的经济评估.

关键词:

塞米普利马布加化学疗法经济效益性经济效益性非小细胞肺癌是非小细胞肺癌.分区生存方法的方法.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...